230P - Selective gastric cancer patients with peritoneal dissemination benefit from palliative gastrectomy after palliative chemotherapy: Results from two...

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cytotoxic agents
Gastric Cancer
Surgical oncology
Presenter Run-Cong Nie
Citation Annals of Oncology (2016) 27 (suppl_9): ix68-ix85. 10.1093/annonc/mdw582
Authors R. Nie1, S. Yuan2, X. Chen1, Y. Chen1
  • 1Department Of Gastric And Pancreatic Surgery, Cancer Centre Sun Yat-Sen University, 510060 - Guangzhou/CN
  • 2Department Of Gastric And Pancreatic Surgery, Cancer Centre Sun Yat-Sen University, Guangzhou/CN

Abstract

Background

To explore whether palliative gastrectomy is suitable for gastric cancer patients with peritoneal metastasis after palliative chemotherapy.

Methods

A total of 200 patients were diagnosed with gastric adenocarcinoma with peritoneal metastasis and were treated with palliative chemotherapy afterwards between January 2000 and April 2014 at our centers. The clinicopathologic characteristics and clinical outcomes of the patients were analyzed.

Results

This study included 34 patients in the gastrectomy group and 166 patients in the non-gastrectomy group. In the gastrectomy group, tumor were smaller (P = 0.025), ascites were less (P = 0.008), peritoneal seeding were less severe (P = 0.005), the period of first chemotherapy was increased (P 

Conclusions

Palliative gastrectomy can prolong the survival of gastric cancer patients with peritoneal metastasis when patients achieve disease control after chemotherapy. In addition, the period of first-line chemotherapy should be more than 5 periods, particularly more than 8 periods.

Clinical trial indentification

Legal entity responsible for the study

Run-Cong Nie

Funding

National Natural Science Foundation of China (81302144)

Disclosure

All authors have declared no conflicts of interest.